InvestorsHub Logo
Followers 72
Posts 4827
Boards Moderated 0
Alias Born 01/24/2004

Re: stoneroad post# 119911

Tuesday, 04/23/2013 7:19:57 PM

Tuesday, April 23, 2013 7:19:57 PM

Post# of 345554
SR, per the latest 10-K (4-30-12 iss. 7-16-12), royalty %'s payable to UTSW/Dallas on sales of future-approved Bavituximab will be in the "low single digits"

4-30-12 10K (iss. 7-16-12) http://tinyurl.com/79o57b2
Pg.10 IN-LICENSING COLLABORATIONS
PS-Targeting Program
Bavituximab
In Aug. 2001 & Aug. 2005, we exclusively in-licensed the worldwide rights to the PS-targeting technology platform from the UT Southwestern Medical Center at Dallas (“UTSWMC”), including bavituximab. . .

Under our in-licensing agreements relating to bavituximab, we typically pay an up-front license fee, annual maintenance fees, and are obligated to pay future milestone payments based on potential clinical development and regulatory milestones, plus a royalty on net sales and/or a percentage of sublicense income. The applicable royalty rate under each of the foregoing in-licensing agreements is in the low single digits. The following table provides certain information with respect to each of our in-licensing agreements relating to our bavituximab program.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News